Radar on Specialty Pharmacy

Study Reinforces Link Between Adherence, Total Medical Costs, Patient Outcomes

  • Feb 13
    Popup Image

    Feb 13, 2025

    Patient nonadherence to therapy can be an issue for people with cancer, despite the potential for poor prognosis and remission, several studies have found. A recent study from Walgreen Co. is reinforcing the idea that supporting cancer patients and giving them tools to help remain adherent can benefit both patients and payers.

    Walgreens’ Connected Care Oncology (CC-Onc) is a patient-centered clinical management program that offers 21 oral hematological cancer therapies. The program utilizes a high-touch, personalized approach to boost adherence and improve outcomes. Researchers sought to find “significant associations” between discontinuation rates for those oral oncolytics and total medical costs, hospitalizations and inpatient length of stay, according to a recent poster presentation.

    Read more
      • Radar on Specialty Pharmacy
    © 2024 MMIT

    • Angela Maas

    Angela has an extensive background of editing, reporting and writing for trade and consumer publications. She has written Radar on Specialty Pharmacy since she joined AIS Health in 2005 and has broad knowledge of the various issues at play within the space. She also has written for Spotlight on Market Access since its 2017 launch. Before joining AIS Health, she was managing editor at Employee Benefit News and Employee Benefit News Canada and managing editor at Hem Aware (a hemophilia publication), Lupus Living and Momentum (a multiple sclerosis publication). She has a B.A. in English and an M.A. in British literature from Arizona State University.

    Back to Radar on Specialty Pharmacy

Related Posts

The Latest
Premium Categories
Meet Our Reporters

Lauren Flynn Kelly

Executive Editor, AIS Health, and Managing Editor, Radar on Medicare Advantage

View Lauren Flynn Kelly's Profile

Angela Maas

Managing Editor, Radar on Specialty Pharmacy and Spotlight on Market Access

View Angela Maas's Profile

Leslie Small

Managing Editor, Health Plan Weekly and Radar on Drug Benefits

View Leslie Small's Profile

Tim Casey

Reporter, Health Plan Weekly and Radar on Drug Benefits

View Tim Casey’s Profile

Carina Belles

Reporter, Radar on Medicare Advantage and Spotlight on Market Access

View Carina Belles's Profile

Jinghong Chen

Reporter, Health Plan Weekly and Radar on Drug Benefits

View Jinghong Chen's Profile

Jill Drachenberg

Reporter, Health Plan Weekly and Radar on Drug Benefits

View Jill Drachenberg's Profile

Meet Our Reporters

Lauren Flynn Kelly

Executive Editor, AIS Health, and Managing Editor, Radar on Medicare Advantage

View Lauren Flynn Kelly's Profile

Angela Maas

Managing Editor, Radar on Specialty Pharmacy and Spotlight on Market Access

View Angela Maas's Profile

Leslie Small

Managing Editor, Health Plan Weekly and Radar on Drug Benefits

View Leslie Small's Profile

Tim Casey

Reporter, Health Plan Weekly and Radar on Drug Benefits

View Tim Casey’s Profile

Carina Belles

Reporter, Radar on Medicare Advantage and Spotlight on Market Access

View Carina Belles's Profile

Jinghong Chen

Reporter, Health Plan Weekly and Radar on Drug Benefits

View Jinghong Chen's Profile

Jill Drachenberg

Reporter, Health Plan Weekly and Radar on Drug Benefits

View Jill Drachenberg's Profile

Tags
Benefit Management
Benefit Design
Oncology
Specialty Drugs
Care Coordination
×

PREMIUM CONTENT AND PREMIUM INSIGHTS

To gain access to this article you need to have a Premium Subscription.
Click the link below to access today!